Nutra Pharma Corp.
NPHC
$0.00
$0.000.00%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -44.14% | -24.84% | -1.76% | 11.56% | 6.28% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -44.14% | -24.84% | -1.76% | 11.56% | 6.28% |
| Cost of Revenue | -15.84% | 18.54% | 45.10% | 18.31% | 33.79% |
| Gross Profit | -62.72% | -50.18% | -29.15% | 7.59% | -6.33% |
| SG&A Expenses | 35.60% | 35.10% | 45.48% | 32.44% | 14.69% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.18% | 33.18% | 45.42% | 30.71% | 16.75% |
| Operating Income | -63.02% | -59.88% | -66.45% | -39.95% | -22.32% |
| Income Before Tax | -255.00% | 51.31% | -59.25% | -37.90% | -16.06% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -255.00% | 51.31% | -59.25% | -37.90% | -16.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -255.00% | 51.31% | -59.25% | -37.90% | -16.06% |
| EBIT | -63.02% | -59.88% | -66.45% | -39.95% | -22.32% |
| EBITDA | -63.46% | -60.04% | -66.69% | -40.02% | -22.89% |
| EPS Basic | -300.00% | -50.00% | -300.00% | -200.00% | -100.00% |
| Normalized Basic EPS | -200.00% | 100.00% | -- | -- | -- |
| EPS Diluted | -300.00% | -50.00% | -300.00% | -200.00% | -100.00% |
| Normalized Diluted EPS | -200.00% | 100.00% | -- | -- | -- |
| Average Basic Shares Outstanding | 3.11% | 2.34% | 1.37% | 1.29% | 0.91% |
| Average Diluted Shares Outstanding | -47.74% | 99.92% | 99.05% | 99.34% | 99.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |